ARGX

argenx
ARGX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$35.09B
EV
$31.49B
Shares Outstanding
-
Beta
-

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$761.26
P/E 2025E
40.24x
P/Revenue 2025E
9.51x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About argenx SE

gainify
ARGX

argenx SE

ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia ...

Sector

Healthcare

Industry

Biotechnology

CEO

Van Hauwermeiren, Timothy

Employees

1,599

Website

argenx.com

IPO Date

2017-05-18

Headquarters

Laarderhoogtweg 25, Amsterdam, Noord-Holland, 1101 EB, Netherlands

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.